Both cryopreserved and live Repository strains can be quickly and efficiently expanded to deliver cohorts directly into your discovery program. With JAX® Dedicated Supply Service and JAX® Speed Expansion Service you'll get the mice you need when you need them — fast.
| Stock Number |
Strain Name Strain Description |
Standard Supply |
| 002269 | B6.129S6-Cd4tm1Knw/J | Repository- Live |
| Mice homozygous for the Cd4tm1Knw targeted mutation have a significant block in CD4+ T cell development; 90% of their circulating T cells are CD8+. Homozygous mutant mice also show a Class II restricted deficit in helper T cell activity and other T cell responses. | ||
| 014639 | C57BL/6-Tg(Cd4-TcraDN32D3)1Aben/J | Repository- Live |
| Vα14-Jα18 transgenic mice contain CD4 promoter/enhancer elements driving expression of prearranged Vα14-Jα18 T cell receptor (TCR) cDNA from hybridoma line DN32.D3. Hemizygous mice are viable and fertile. These mice overexpress Natural Killer T (NKT) cells, or Vα14 NKT cells, in the liver, thymus, spleen, and lymph nodes. These mice may be useful for studying positive/negative selection, T cell receptor interactions, and NKT cell function. | ||
| 014644 | C57BL/6-Tg(Cd4-Zbtb16)1797Aben/J | Repository- Live |
| CD4-PLZF transgenic mice contain CD4 promoter/enhancer elements driving expression of the zinc finger and BTB domain containing 16 (Zbtb16 or PLZF) cDNA from purified natural killer T (NKT cells). Hemizygous mice are viable and fertile. PLZF is a transcriptional regulator that is expressed in NKT cells and is required for their maturation into effector-type lymphocytes. Transgenic expression of PLZF using the CD4 promoter induces
conventional CD4 T cells to acquire effector characteristics. While
CD4 T cells are present at normal levels in the thymus, spleen, liver,
and lungs of the CD4-PLZF mouse, they are nearly absent in the blood
and lymph nodes. Greater than 98% of mature CD4 T cells display a
CD44hi/CD62Llo effector phenotype. An increased percentage of CD4 T cells produce both interleukin-4 (IL-4) and interferon (IFN) γ upon TCR stimulation. These mice may be useful for studying the function
of PLZ ..... For more information please see the full phenotype on the strain data sheet | ||
| 002447 | B10.129S2(B6)-Cd4tm1Litt/J | Cryopreserved - Ready for recovery |
| Mice homozygous for the Cd4tm1 targeted mutation have a significant block in CD4+ T cell development; 90% of their circulating T cells are CD8+. Homozygous mutant mice also show a Class II restricted deficit in helper T cell activity and other T cell responses. | ||
| 002268 | B6;129S6-Cd4tm1Knw/J | Cryopreserved - Ready for recovery |
| Mice homozygous for the Cd4tm1Knw targeted mutation have a significant block in CD4+ T cell development; 90% of their circulating T cells are CD8+. Homozygous mutant mice also show a Class II restricted deficit in helper T cell activity and other T cell responses. | ||
| 012895 | C57BL/6-Tg(Cd4-Il17rb)5Cdon/J | Cryopreserved - Ready for recovery |
| These transgenic mice express the mouse interleukin 17 receptor B under the direction of the mouse CD4 antigen promoter/enhancer. Mice hemizygous for the transgenic insert are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. The Donating Investigator has not attempted to make the strain homozygous. The transgene is expressed in all T cells. When treated with IL25, T cells from transgenic mice have reduced numbers of IFN-gamma producing cells, reduced IL4 and IFN-gamma levels and increased IL5 and IL13 levels when compared to wildtype. Transgenic mice challenged with intranasal allergens exhibit higher levels of inflammatory cell infiltration than wildtype controls. | ||
| 003090 | NOD.129S6(B6)-Cd4tm1Knw/DvsJ | Cryopreserved - Ready for recovery |
| 005328 | NOD/ShiLt-Tg(Cd4-DsRed)4Lt/J | Cryopreserved - Ready for recovery |
| The donating investigator reports that hemizygous transgenic mice are viable, fertile and normal in size. FACS analysis of splenic lymphocytes shows transgenic expression in 36% of CD4+ and 6% of CD8+ T cells and minimal expression (background levels) in B cells and macrophages. When compared to wild-type NOD/ShiLt mice, the diabetes incidence is lower (50%) and diabetes onset is delayed. Adoptive transfer experiments with splenocytes and bone marrow from hemizygous CD4-DsRed transgenic mice does not confer diabetes protection on NOD inbred mice, suggesting that the agent of protection is not dependent on hematopoietic cells. No homozygous transgenic mice have been identified in litters produced from hemizygote intercrosses, suggesting that homozygotes are not viable. This strain is useful for tracking resting and activated T cells in vivo and in vitro. | ||
| 010514 | B10.Cg-H2g Tg(Cd4-Klra1)6295Dl/J | Awaiting Transfer from the Donor |
| These Ly-49A transgenic mice express the mouse Klra1 (killer cell lectin-like receptor, subfamily A, member 1) gene under the control of a modified mouse CD4 antigen (Cd4) promoter (this promoter lacks the silencer element sequence suppressing expression in CD8 T cells). Transgene expression is detected during early T cell development and throughout CD4 and CD8 T cell differentiation and migration. This mutant mouse strain may be useful in studies of autoimmune and inflammatory diseases. | ||
Send questions to our Technical Support team using the Express Technical Support Form.
(5.1)